Imunon, Inc. (IMNN) AI Stock Analysis
IMNN AI stock analysis summary
AI ResearchImunon, Inc. is a clinical-stage biotechnology company developing DNA-based immunotherapies and targeted chemotherapies. For the trailing twelve months ended June 30, 2026, the company generated revenue of $125,000 and recorded diluted EPS of -$3.84. Its stock closed at $1.02 on October 16, 2026, reflecting a 1-year return of -79.8% against a market capitalization of $5.7M.
- Market cap
- $5.7M
- Revenue (TTM)
- $125,000
- P/E
- — fwd 16.8x
- 1Y return
- -79.8% S&P 500 16.8%
- Avg. target
- $17.00 1566.7% vs last close
Bull case
- Analysts hold 3 Strong Buy ratings and 1 Buy rating with a mean price target of $17.00, which is 1566.7% above the last close.
- Imunon beat analyst EPS estimates in all 4 of its last 4 quarters.
- The company holds $6.9M in cash and short-term investments alongside a current ratio of 1.82 as of June 30, 2026.
Bear case
- Revenue fell 75.0% to $125,000 in FY2023, yielding a 5-year revenue CAGR of -24.2%.
- Net losses remained substantial at -$19.5M in FY2023, accompanied by negative free cash flow of -$19.5M.
- Shareholder dilution has been heavy, with share count increasing 1082.8% over five years, contributing to a 5-year stock return of -99.4%.
What Imunon does
Imunon, Inc. is a clinical-stage biotechnology company headquartered in Lawrenceville, New Jersey. Founded in 1982 and formerly known as Celsion Corporation until September 2022, the company advances DNA-based immunotherapies, vaccines, and targeted chemotherapies. Its clinical pipeline features GEN-1, a DNA-based immunotherapy designed for localized treatment of ovarian cancer patients. Imunon is also developing ThermoDox, a proprietary heat-activated formulation of liposomal doxorubicin for various cancer indications. In addition, the company possesses platform technologies in the feasibility stage aimed at advancing nucleic acid-based immunotherapies and DNA or RNA therapies across oncology.
Growth and profitability
Between FY2019 and FY2022, annual revenue held steady at $500,000 before falling 75.0% to $125,000 in FY2023. This drop contributed to a 5-year revenue CAGR of -24.2% from FY2018 to FY2023. Net losses widened from -$16.9M in FY2019 to -$35.9M in FY2022, before reaching -$19.5M in FY2023. Gross margin shifted from 100.0% in FY2022 to -576.0% in FY2023, while operating margin was -16824.3%. Annual R&D expense stood at $11.3M in FY2023. For the trailing twelve months ended June 30, 2026, revenue was $125,000, operating margin was 0.0%, and EPS was -$3.84.
Balance sheet and cash flow
As of June 30, 2026, Imunon reported cash and short-term investments of $6.9M and total assets of $15.0M. Total debt stood at $7.8M, yielding net debt of $980,914 and a debt-to-equity ratio of 1.87 against shareholders' equity of $4.2M. The company maintained a current ratio of 1.82. Free cash flow was -$19.5M in FY2023, driven by an operating cash flow of -$19.0M. In FY2025, capital expenditures totaled $280,572, while the 5-year share count change reached 1082.8%.
Valuation and performance
Imunon has a market capitalization of $5.7M and an enterprise value of $9.2M. The stock trades at a price-to-sales multiple of 17.9x, above the median of its US-listed Healthcare peers of 4.1x. Its forward P/E ratio is 16.8x, compared to 17.3x for the peer median. The company trades at an EV to EBITDA ratio of 0.9x versus 12.0x for its peer group. Over the past year, IMNN delivered a return of -79.8%, while the S&P 500 (SPY) returned 16.8%. Over five years, the stock returned -99.4% compared to 83.0% for the S&P 500.
What analysts expect
Four analysts cover Imunon, with 3 Strong Buy ratings, 1 Buy rating, and 0 Hold or Sell ratings. The mean price target is $17.00, representing an increase of 1566.7% over the last close of $1.02. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$2.33 on $0 in revenue. For the next fiscal year, projected EPS is -$1.77 on $0 in revenue. Imunon beat EPS estimates in each of its last 4 quarters, and its next earnings date is November 12, 2026.
Key risks and what to watch
- The company's total debt of $7.8M exceeds its cash and short-term investments of $6.9M, leaving net debt at $980,914 as of June 30, 2026.
- With revenue estimated at $0 for both FY2026 and the following fiscal year, commercial revenue generation remains uncertain.
- A high beta of 2.00 reflects elevated stock volatility, which contributed to a year-to-date return of -73.2%.
- Imunon generated negative operating cash flow of -$19.0M in FY2023, creating ongoing financing demands.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this IMNN AI stock analysis
This page is an AI-written research summary of Imunon, Inc. (IMNN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: IMNN income statement, IMNN balance sheet, IMNN key metrics, IMNN analyst forecast, IMNN chart. See the IMNN stock overview for the latest quote and news.
IMNN AI stock analysis FAQ
What does Imunon, Inc. do?
Imunon is a clinical-stage biotechnology company that develops DNA-based immunotherapies, vaccines, and targeted chemotherapies, including its lead candidate GEN-1 for ovarian cancer.
What is Imunon's current stock price and valuation?
As of October 16, 2026, Imunon's stock closed at $1.02, giving the company a market capitalization of $5.7M and an enterprise value of $9.2M.
What are analysts forecasting for Imunon?
Analysts project an EPS of -$2.33 on $0 of revenue for FY2026, improving to an EPS of -$1.77 on $0 of revenue next fiscal year. The mean price target is $17.00.
What is Imunon's cash and debt position?
As of June 30, 2026, Imunon held $6.9M in cash and short-term investments against $7.8M in total debt, resulting in net debt of $980,914 and a current ratio of 1.82.
When does Imunon report earnings next?
Imunon's next earnings date is scheduled for November 12, 2026.